Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 361 to 370 of 370 entries
Sorted by: Best Match Show Resources per page
Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data.

Epilepsy & behavior : E&B

Schubert-Bast S, Kay L, Simon A, Wyatt G, Holland R, Rosenow F, Strzelczyk A.
PMID: 34864381
Epilepsy Behav. 2021 Dec 01;126:108442. doi: 10.1016/j.yebeh.2021.108442. Epub 2021 Dec 01.

OBJECTIVE: Ten-year retrospective study to assess burden of illness in patients with probable Dravet syndrome (DS) identified from German healthcare data.METHODS: In the absence of an International Classification of Diseases code, patients with probable DS were identified using a...

Cite
Schubert-Bast S, Kay L, Simon A, et al. Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data. Epilepsy Behav. 2021;126:108442doi: 10.1016/j.yebeh.2021.108442.
Schubert-Bast, S., Kay, L., Simon, A., Wyatt, G., Holland, R., Rosenow, F., & Strzelczyk, A. (2021). Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data. Epilepsy & behavior : E&B, 126108442. https://doi.org/10.1016/j.yebeh.2021.108442
Schubert-Bast, Susanne, et al. "Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data." Epilepsy & behavior : E&B vol. 126 (2021): 108442. doi: https://doi.org/10.1016/j.yebeh.2021.108442
Schubert-Bast S, Kay L, Simon A, Wyatt G, Holland R, Rosenow F, Strzelczyk A. Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data. Epilepsy Behav. 2021 Dec 01;126:108442. doi: 10.1016/j.yebeh.2021.108442. Epub 2021 Dec 01. PMID: 34864381.
Copy Download .nbib Format: NLM
GRADE Guidance 24. Optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines.

Journal of clinical epidemiology

Cuello-Garcia CA, Santesso N, Morgan RL, Verbeek J, Thayer K, Ansari MT, Meerpohl J, Schwingshackl L, Katikireddi SV, Brozek JL, Reeves B, Murad MH, Falavigna M, Mustafa R, Regidor DL, Alexander PE, Garner P, Akl EA, Guyatt G, Schünemann HJ.
PMID: 34800676
J Clin Epidemiol. 2021 Nov 17; doi: 10.1016/j.jclinepi.2021.11.026. Epub 2021 Nov 17.

This is the 24th in the ongoing series of articles describing the GRADE approach for assessing the certainty of a body of evidence in systematic reviews and health technology assessments and how to move from evidence to recommendations in...

Cite
Cuello-Garcia CA, Santesso N, Morgan RL, et al. GRADE Guidance 24. Optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines. J Clin Epidemiol. 2021;doi: 10.1016/j.jclinepi.2021.11.026.
Cuello-Garcia, C. A., Santesso, N., Morgan, R. L., Verbeek, J., Thayer, K., Ansari, M. T., Meerpohl, J., Schwingshackl, L., Katikireddi, S. V., Brozek, J. L., Reeves, B., Murad, M. H., Falavigna, M., Mustafa, R., Regidor, D. L., Alexander, P. E., Garner, P., Akl, E. A., Guyatt, G., & Schünemann, H. J. (2021). GRADE Guidance 24. Optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines. Journal of clinical epidemiology, . https://doi.org/10.1016/j.jclinepi.2021.11.026
Cuello-Garcia, Carlos A, et al. "GRADE Guidance 24. Optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines." Journal of clinical epidemiology vol. (2021). doi: https://doi.org/10.1016/j.jclinepi.2021.11.026
Cuello-Garcia CA, Santesso N, Morgan RL, Verbeek J, Thayer K, Ansari MT, Meerpohl J, Schwingshackl L, Katikireddi SV, Brozek JL, Reeves B, Murad MH, Falavigna M, Mustafa R, Regidor DL, Alexander PE, Garner P, Akl EA, Guyatt G, Schünemann HJ. GRADE Guidance 24. Optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines. J Clin Epidemiol. 2021 Nov 17; doi: 10.1016/j.jclinepi.2021.11.026. Epub 2021 Nov 17. PMID: 34800676.
Copy Download .nbib Format: NLM
Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis.

Critical care explorations

Ye Z, Wang Y, Ge L, Guyatt GH, Collister D, Alhazzani W, Bagshaw SM, Belley-Cote EP, Fang F, Hou L, Kolb P, Lamontagne F, Oczkowski S, Pyne L, Rabbat C, Scaum M, Najafabadi BT, Tangamornsuksan W, Wald R, Wang Q, Walsh M, Yao L, Zeng L, Algarni AM, Couban RJ, Alexander PE, Rochwerg B.
PMID: 34079944
Crit Care Explor. 2021 May 12;3(5):e0399. doi: 10.1097/CCE.0000000000000399. eCollection 2021 May.

OBJECTIVES: To compare different modalities of renal replacement therapy in critically ill adults with acute kidney injury.DATA SOURCES: We searched Medline, PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to 25 May, 2020. We included...

Cite
Ye Z, Wang Y, Ge L, et al. Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Crit Care Explor. 2021;3(5):e0399doi: 10.1097/CCE.0000000000000399.
Ye, Z., Wang, Y., Ge, L., Guyatt, G. H., Collister, D., Alhazzani, W., Bagshaw, S. M., Belley-Cote, E. P., Fang, F., Hou, L., Kolb, P., Lamontagne, F., Oczkowski, S., Pyne, L., Rabbat, C., Scaum, M., Najafabadi, B. T., Tangamornsuksan, W., Wald, R., Wang, Q., Walsh, M., Yao, L., Zeng, L., Algarni, A. M., Couban, R. J., Alexander, P. E., & Rochwerg, B. (2021). Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Critical care explorations, 3(5), e0399. https://doi.org/10.1097/CCE.0000000000000399
Ye, Zhikang, et al. "Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis." Critical care explorations vol. 3,5 (2021): e0399. doi: https://doi.org/10.1097/CCE.0000000000000399
Ye Z, Wang Y, Ge L, Guyatt GH, Collister D, Alhazzani W, Bagshaw SM, Belley-Cote EP, Fang F, Hou L, Kolb P, Lamontagne F, Oczkowski S, Pyne L, Rabbat C, Scaum M, Najafabadi BT, Tangamornsuksan W, Wald R, Wang Q, Walsh M, Yao L, Zeng L, Algarni AM, Couban RJ, Alexander PE, Rochwerg B. Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Crit Care Explor. 2021 May 12;3(5):e0399. doi: 10.1097/CCE.0000000000000399. eCollection 2021 May. PMID: 34079944; PMCID: PMC8162503.
Copy Download .nbib Format: NLM
Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials.

European urology focus

Kilpeläinen TP, Tikkinen KAO, Guyatt GH, Vernooij RWM.
PMID: 34688589
Eur Urol Focus. 2021 Nov;7(6):1237-1239. doi: 10.1016/j.euf.2021.10.001. Epub 2021 Oct 20.

In randomized controlled trials, investigators often explore the possibility that the treatment effects differ between subgroups (eg, women vs men, old vs young, more versus less severe disease). Investigators often inappropriately claim subgroup effects (also called "effect modification" or...

Cite
Kilpeläinen TP, Tikkinen KAO, Guyatt GH, et al. Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials. Eur Urol Focus. 2021;7(6):1237-1239doi: 10.1016/j.euf.2021.10.001.
Kilpeläinen, T. P., Tikkinen, K. A. O., Guyatt, G. H., & Vernooij, R. W. M. (2021). Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials. European urology focus, 7(6), 1237-1239. https://doi.org/10.1016/j.euf.2021.10.001
Kilpeläinen, Tuomas P, et al. "Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials." European urology focus vol. 7,6 (2021): 1237-1239. doi: https://doi.org/10.1016/j.euf.2021.10.001
Kilpeläinen TP, Tikkinen KAO, Guyatt GH, Vernooij RWM. Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials. Eur Urol Focus. 2021 Nov;7(6):1237-1239. doi: 10.1016/j.euf.2021.10.001. Epub 2021 Oct 20. PMID: 34688589.
Copy Download .nbib Format: NLM
Malonate Promotes Adult Cardiomyocyte Proliferation and Heart Regeneration.

Circulation

Bae J, Salamon RJ, Brandt EB, Paltzer WG, Zhang Z, Britt EC, Hacker TA, Fan J, Mahmoud AI.
PMID: 33666092
Circulation. 2021 May 18;143(20):1973-1986. doi: 10.1161/CIRCULATIONAHA.120.049952. Epub 2021 Mar 05.

BACKGROUND: Neonatal mouse cardiomyocytes undergo a metabolic switch from glycolysis to oxidative phosphorylation, which results in a significant increase in reactive oxygen species production that induces DNA damage. These cellular changes contribute to cardiomyocyte cell cycle exit and loss...

Cite
Bae J, Salamon RJ, Brandt EB, et al. Malonate Promotes Adult Cardiomyocyte Proliferation and Heart Regeneration. Circulation. 2021;143(20):1973-1986doi: 10.1161/CIRCULATIONAHA.120.049952.
Bae, J., Salamon, R. J., Brandt, E. B., Paltzer, W. G., Zhang, Z., Britt, E. C., Hacker, T. A., Fan, J., & Mahmoud, A. I. (2021). Malonate Promotes Adult Cardiomyocyte Proliferation and Heart Regeneration. Circulation, 143(20), 1973-1986. https://doi.org/10.1161/CIRCULATIONAHA.120.049952
Bae, Jiyoung, et al. "Malonate Promotes Adult Cardiomyocyte Proliferation and Heart Regeneration." Circulation vol. 143,20 (2021): 1973-1986. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.049952
Bae J, Salamon RJ, Brandt EB, Paltzer WG, Zhang Z, Britt EC, Hacker TA, Fan J, Mahmoud AI. Malonate Promotes Adult Cardiomyocyte Proliferation and Heart Regeneration. Circulation. 2021 May 18;143(20):1973-1986. doi: 10.1161/CIRCULATIONAHA.120.049952. Epub 2021 Mar 05. PMID: 33666092; PMCID: PMC8131241.
Copy Download .nbib Format: NLM
Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data.

Journal of clinical epidemiology

Torres Roldan VD, Ponce OJ, Urtecho M, Torres GF, Belluzzo T, Montori V, Liu C, Barrera F, Diaz A, Prokop L, Guyatt G, Montori VM.
PMID: 34400257
J Clin Epidemiol. 2021 Nov;139:160-166. doi: 10.1016/j.jclinepi.2021.08.006. Epub 2021 Aug 13.

BACKGROUND AND OBJECTIVE: Recommendations for preventing cardiovascular (CV) disease are currently separated into primary and secondary prevention. We hypothesize that relative effects of interventions for CV prevention are not different across primary and secondary prevention cohorts. Our aim was...

Cite
Torres Roldan VD, Ponce OJ, Urtecho M, et al. Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data. J Clin Epidemiol. 2021;139:160-166doi: 10.1016/j.jclinepi.2021.08.006.
Torres Roldan, V. D., Ponce, O. J., Urtecho, M., Torres, G. F., Belluzzo, T., Montori, V., Liu, C., Barrera, F., Diaz, A., Prokop, L., Guyatt, G., & Montori, V. M. (2021). Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data. Journal of clinical epidemiology, 139160-166. https://doi.org/10.1016/j.jclinepi.2021.08.006
Torres Roldan, Victor D, et al. "Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data." Journal of clinical epidemiology vol. 139 (2021): 160-166. doi: https://doi.org/10.1016/j.jclinepi.2021.08.006
Torres Roldan VD, Ponce OJ, Urtecho M, Torres GF, Belluzzo T, Montori V, Liu C, Barrera F, Diaz A, Prokop L, Guyatt G, Montori VM. Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data. J Clin Epidemiol. 2021 Nov;139:160-166. doi: 10.1016/j.jclinepi.2021.08.006. Epub 2021 Aug 13. PMID: 34400257.
Copy Download .nbib Format: NLM
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.

The Lancet. Global health

Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ.
PMID: 34717820
Lancet Glob Health. 2021 Oct 27; doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 27.

BACKGROUND: Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention...

Cite
Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021;doi: 10.1016/S2214-109X(21)00448-4.
Reis, G., Dos Santos Moreira-Silva, E. A., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., Dos Santos, C. V. Q., de Souza Campos, V. H., Nogueira, A. M. R., de Almeida, A. P. F. G., Callegari, E. D., de Figueiredo Neto, A. D., Savassi, L. C. M., Simplicio, M. I. C., Ribeiro, L. B., Oliveira, R., Harari, O., Forrest, J. I., Ruton, H., Sprague, S., McKay, P., Glushchenko, A. V., Rayner, C. R., Lenze, E. J., Reiersen, A. M., Guyatt, G. H., Mills, E. J. (2021). Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet. Global health, . https://doi.org/10.1016/S2214-109X(21)00448-4
Reis, Gilmar, et al. "Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial." The Lancet. Global health vol. (2021). doi: https://doi.org/10.1016/S2214-109X(21)00448-4
Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021 Oct 27; doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 27. PMID: 34717820; PMCID: PMC8550952.
Copy Download .nbib Format: NLM
The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials.

Journal of cardiovascular development and disease

Astaneh B, Makhdami N, Astaneh V, Guyatt G.
PMID: 34357325
J Cardiovasc Dev Dis. 2021 Jul 20;8(7). doi: 10.3390/jcdd8070082.

No abstract available.

Cite
Astaneh B, Makhdami N, Astaneh V, et al. The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials. J Cardiovasc Dev Dis. 2021;8(7)doi: 10.3390/jcdd8070082.
Astaneh, B., Makhdami, N., Astaneh, V., & Guyatt, G. (2021). The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials. Journal of cardiovascular development and disease, 8(7), . https://doi.org/10.3390/jcdd8070082
Astaneh, Behrooz, et al. "The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials." Journal of cardiovascular development and disease vol. 8,7 (2021). doi: https://doi.org/10.3390/jcdd8070082
Astaneh B, Makhdami N, Astaneh V, Guyatt G. The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials. J Cardiovasc Dev Dis. 2021 Jul 20;8(7). doi: 10.3390/jcdd8070082. PMID: 34357325; PMCID: PMC8304130.
Copy Download .nbib Format: NLM
Association between routine measures of graft function and mortality in heart transplant recipients.

Heart (British Cardiac Society)

Foroutan F, Malik A, Nelson LMS, Steve CF, Guyatt G, Gustafsson F, Ross H, Alba AC.
PMID: 33707225
Heart. 2021 Mar 11; doi: 10.1136/heartjnl-2020-318721. Epub 2021 Mar 11.

OBJECTIVE: To date, long-term graft dysfunction, an important cause of death after heart transplantation, has been defined as a left ventricular ejection fraction (LVEF) of ≤40% or right atrial pressure (RAP) of ≥15 mm Hg. Empirical associations between measures...

Cite
Foroutan F, Malik A, Nelson LMS, et al. Association between routine measures of graft function and mortality in heart transplant recipients. Heart. 2021;doi: 10.1136/heartjnl-2020-318721.
Foroutan, F., Malik, A., Nelson, L. M. S., Steve, C. F., Guyatt, G., Gustafsson, F., Ross, H., & Alba, A. C. (2021). Association between routine measures of graft function and mortality in heart transplant recipients. Heart (British Cardiac Society), . https://doi.org/10.1136/heartjnl-2020-318721
Foroutan, Farid, et al. "Association between routine measures of graft function and mortality in heart transplant recipients." Heart (British Cardiac Society) vol. (2021). doi: https://doi.org/10.1136/heartjnl-2020-318721
Foroutan F, Malik A, Nelson LMS, Steve CF, Guyatt G, Gustafsson F, Ross H, Alba AC. Association between routine measures of graft function and mortality in heart transplant recipients. Heart. 2021 Mar 11; doi: 10.1136/heartjnl-2020-318721. Epub 2021 Mar 11. PMID: 33707225.
Copy Download .nbib Format: NLM
A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes.

Journal of clinical epidemiology

Wang Y, Devji T, Qasim A, Hao Q, Wong V, Bhatt M, Prasad M, Wang Y, Noori A, Xiao Y, Ghadimi M, Lozano LEC, Phillips MR, Carrasco-Labra A, King M, Terluin B, Terwee CB, Walsh M, Furukawa TA, Guyatt GH.
PMID: 34752937
J Clin Epidemiol. 2021 Nov 06;142:144-151. doi: 10.1016/j.jclinepi.2021.10.028. Epub 2021 Nov 06.

OBJECTIVE: To systematically survey the literature addressing the reporting of studies estimating anchor-based minimal important differences (MIDs) and choice of optimal MIDs.STUDY DESIGN AND SETTING: We searched Medline, Embase and PsycINFO from 1987 to March 2020. Teams of two...

Cite
Wang Y, Devji T, Qasim A, et al. A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes. J Clin Epidemiol. 2021;142:144-151doi: 10.1016/j.jclinepi.2021.10.028.
Wang, Y., Devji, T., Qasim, A., Hao, Q., Wong, V., Bhatt, M., Prasad, M., Wang, Y., Noori, A., Xiao, Y., Ghadimi, M., Lozano, L. E. C., Phillips, M. R., Carrasco-Labra, A., King, M., Terluin, B., Terwee, C. B., Walsh, M., Furukawa, T. A., & Guyatt, G. H. (2021). A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes. Journal of clinical epidemiology, 142144-151. https://doi.org/10.1016/j.jclinepi.2021.10.028
Wang, Yuting, et al. "A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes." Journal of clinical epidemiology vol. 142 (2021): 144-151. doi: https://doi.org/10.1016/j.jclinepi.2021.10.028
Wang Y, Devji T, Qasim A, Hao Q, Wong V, Bhatt M, Prasad M, Wang Y, Noori A, Xiao Y, Ghadimi M, Lozano LEC, Phillips MR, Carrasco-Labra A, King M, Terluin B, Terwee CB, Walsh M, Furukawa TA, Guyatt GH. A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes. J Clin Epidemiol. 2021 Nov 06;142:144-151. doi: 10.1016/j.jclinepi.2021.10.028. Epub 2021 Nov 06. PMID: 34752937.
Copy Download .nbib Format: NLM
Showing 361 to 370 of 370 entries